During the last session, Immuneering Corp (NASDAQ:IMRX)’s traded shares were 0.42 million, with the beta value of the company hitting -0.45. At the end of the trading day, the stock’s price was $2.19, reflecting an intraday loss of -1.35% or -$0.03. The 52-week high for the IMRX share is $8.89, that puts it down -305.94 from that peak though still a striking 54.34% gain since the share price plummeted to a 52-week low of $1.00. The company’s market capitalization is $64.93M, and the average intraday trading volume over the past 10 days was 0.89 million shares, and the average trade volume was 6.21 million shares over the past three months.

Immuneering Corp (IMRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.57. IMRX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.

Immuneering Corp (NASDAQ:IMRX) trade information

Immuneering Corp (IMRX) registered a -1.35% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.35% in intraday trading to $2.19, hitting a weekly high. The stock’s 5-day price performance is -11.34%, and it has moved by 53.15% in 30 days. Based on these gigs, the overall price performance for the year is -67.26%. The short interest in Immuneering Corp (NASDAQ:IMRX) is 1.63 million shares and it means that shorts have 0.11 day(s) to cover.

The consensus price target of analysts on Wall Street is $13, which implies an increase of 83.15% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $41 respectively. As a result, IMRX is trading at a discount of -1772.15% off the target high and -36.99% off the low.

Immuneering Corp (IMRX) estimates and forecasts

Statistics show that Immuneering Corp has underperformed its competitors in share price, compared to the industry in which it operates. Immuneering Corp (IMRX) shares have gone up 4.29% during the last six months, with a year-to-date growth rate less than the industry average at -0.53% against 17.50.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -57.97%. While earnings are projected to return -0.30% in 2024.

IMRX Dividends

Immuneering Corp is due to release its next quarterly earnings on 2024-Aug-06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Immuneering Corp (NASDAQ:IMRX)’s Major holders

Immuneering Corp insiders own 29.12% of total outstanding shares while institutional holders control 32.46%, with the float percentage being 45.80%. CITADEL ADVISORS LLC is the largest shareholder of the company, while 74.0 institutions own stock in it. As of 2024-06-30, the company held over 1.88 million shares (or 6.4083% of all shares), a total value of $2.41 million in shares.

The next largest institutional holding, with 1.07 million shares, is of VANGUARD GROUP INC’s that is approximately 3.6442% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.37 million.

Also, the Mutual Funds coming in first place with the largest holdings of Immuneering Corp (IMRX) shares are Vanguard Total Stock Market Index Fund and Price (T.Rowe) Health Sciences Fund . Data provided on Jun 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 736.19 shares. This amounts to just over 2.48 percent of the company’s overall shares, with a $1.61 million market value. The same data shows that the other fund manager holds slightly less at 558.38, or about 1.88% of the stock, which is worth about $1.22 million.